Clinical Trial Update: Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of tislelizumab and lenvatinib in hepatocellular carcinoma, reporting preliminary antitumor activity and safety/tolerab…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-03-10